Vantage logo

Sanofi does a spring clean

The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.

Vantage logo

Big caps provide a safe haven

As the curtain came down on a quarter many in biotech would rather forget, big pharma groups stood out by being the least bad investment option.

Vantage logo

Keytruda wins 2018’s biggest sales upgrade

Vantage takes a look at the sellside’s naughty and nice list for 2018: prospects improved considerably for Merck & Co’s Keytruda and Abbvie’s Mavyret, the latter…